IL2RA and lymphoid neoplasm: Autoimmune diseases and a variety of lymphoid neoplasms are also investigated for the therapeutic application of an anti-CD25 antibody as the list of diseases under consideration for a therapeutic modulation of IL-2 signaling is expanding [54].